# Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

> **NCT04281641** · NA · RECRUITING · sponsor: **Fudan University** · enrollment: 94 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** TCHP

## Key facts

- **NCT ID:** NCT04281641
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-21
- **Primary completion:** 2025-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281641, "Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04281641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*